PubRank

Paolo Vigneri

Author PubWeight™ 32.92‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest 2009 3.55
2 Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib. Leuk Res 2011 1.42
3 Cancer stem cells and chemosensitivity. Clin Cancer Res 2011 1.26
4 V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells. J Immunol 2010 1.20
5 HMGA1 inhibits the function of p53 family members in thyroid cancer cells. Cancer Res 2006 1.16
6 Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells. Cancer Res 2006 1.15
7 Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis. Leuk Res 2007 1.13
8 The changing epidemiology of thyroid cancer: why is incidence increasing? Curr Opin Oncol 2015 1.06
9 BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B. Blood 2005 0.99
10 Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib. Haematologica 2011 0.98
11 Exclusion of c-Abl from the nucleus restrains the p73 tumor suppression function. J Biol Chem 2003 0.91
12 Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Acta Oncol 2010 0.90
13 Interplay between kinase domain autophosphorylation and F-actin binding domain in regulating imatinib sensitivity and nuclear import of BCR-ABL. PLoS One 2011 0.90
14 Suppression of survivin induced by a BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs. Mol Cancer Ther 2013 0.88
15 The p53-homologue p63 may promote thyroid cancer progression. Endocr Relat Cancer 2005 0.87
16 Reactivation of p53 mutants by prima-1 [corrected] in thyroid cancer cells. Int J Cancer 2011 0.87
17 p73 tumor-suppressor activity is impaired in human thyroid cancer. Cancer Res 2003 0.87
18 DeltaNp73alpha inhibits PTEN expression in thyroid cancer cells. Int J Cancer 2009 0.82
19 Increased phospho-mTOR expression in megakaryocytic cells derived from CD34+ progenitors of essential thrombocythaemia and myelofibrosis patients. Br J Haematol 2012 0.81
20 Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia. Hematol Oncol 2012 0.81
21 IRF5 promotes the proliferation of human thyroid cancer cells. Mol Cancer 2012 0.81
22 Thyroid cancer cell resistance to gefitinib depends on the constitutive oncogenic activation of the ERK pathway. J Clin Endocrinol Metab 2013 0.78
23 Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia. Ann Hematol 2012 0.78
24 Hyperdiploidy associated with a high BCR-ABL transcript level may identify patients at risk of progression in chronic myeloid leukemia. Acta Haematol 2011 0.77
25 Basal insulin and cardiovascular and other outcomes. N Engl J Med 2012 0.77
26 Biological effects of insulin and its analogs on cancer cells with different insulin family receptor expression. J Cell Physiol 2014 0.77
27 Hammersmith score application identifies chronic myeloid leukemia patients with poor prognosis before treatment with second-generation tyrosine kinase inhibitors. Am J Hematol 2011 0.76
28 Clinical relevance of the association of interferon alfa to imatinib in chronic myeloid leukemia therapy. Int J Hematol 2012 0.76
29 Imatinib dose escalation in 74 failure or suboptimal response chronic myeloid leukaemia patients at 3-year follow-up. Am J Hematol 2010 0.76
30 Imatinib discontinuation: realistic for patients with chronic myeloid leukaemia achieving complete molecular remission? Lancet Oncol 2011 0.76
31 Re: Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2009 0.76
32 Predictive and Prognostic Value of Early Disease Progression by PET Evaluation in Advanced Non-Small Cell Lung Cancer. Oncology 2016 0.76
33 Diagnosis of blastic phase of chronic myeloid leukemia. Acta Haematol 2012 0.75
34 Infliximab therapy in hematologic malignancies: handle with care. Haematologica 2012 0.75
35 Personalized strategies for CML patients considering discontinuation of tyrosine kinase inhibitors treatment. Leuk Res 2012 0.75
36 Uncommon long-term survival in a patient with chronic myeloid leukemia. Acta Oncol 2009 0.75
37 IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation. Carcinogenesis 2014 0.75
38 Unsuccessful dasatinib therapy in a refractory patient with chronic lymphocytic leukemia. Acta Haematol 2010 0.75
39 Towards a need to a "biological Sokal risk" in the era of tyrosine kinase inhibitors in choosing front-line therapy in chronic myeloid leukemia. Leuk Res 2012 0.75
40 Modelling of the ABL and ARG proteins predicts two functionally critical regions that are natively unfolded. Proteins 2007 0.75
41 Roles of Interferon Regulatory Factors in Chronic Myeloid Leukemia. Curr Cancer Drug Targets 2016 0.75
42 Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias. Acta Oncol 2010 0.75
43 Utility of flow cytometry as a screening tool for transplant donors for chronic lymphocytic leukemia. Acta Haematol 2010 0.75